Asset profile
Lotivibart
Monoclonal antibody
Evidence outlook · no controlled comparison
NCT04871113 · HIV Infections
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
NCT04871113: Participants were randomized among dose cohorts, but the study was open-label, had no placebo or active comparator during monotherapy, and included only 6 to 16 participants per cohort. The primary endpoint was the surrogate measure of maximum decline in HIV-1 RNA and was reported descriptively without a formal comparative efficacy test, so the findings do not establish comparative treatment benefit.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 54 same-indication; 32 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Lotivibart: this drug | Phase 2 | Monoclonal antibody | HIV envelope | ||
| Teropavimab | Phase 3 | Monoclonal antibody | HIV envelope | ||
| Zinlirvimab | Phase 3 | Monoclonal antibody | HIV envelope | ||
| 10-1074 | Phase 2 | Monoclonal antibody | HIV envelope | ||
| 3BNC117 | Phase 2 | Monoclonal antibody | HIV envelope | ||
| BNT351 | Phase 1 | Monoclonal antibody | HIV envelope | ||
| UVAX-1107 | Phase 1 | Vaccine | HIV envelope | ||
| Bictegravir (Biktarvy) | Approved | Small molecule | HIV integrase | ||
| Cabotegravir (Vocabria / Cabenuva / Apretude) | Approved | Small molecule | HIV integrase | ||
| Crofelemer (Mytesi) | Approved | Small molecule | Chloride channel (intestinal epithelium) | ||
| Darunavir (Prezista) | Approved | Small molecule | HIV protease | ||
| Dolutegravir (Tivicay / Triumeq / Dovato / Juluca (component)) | Approved | Small molecule | HIV integrase | ||
| Doravirine (Pifeltro) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elsulfavirine (Elpida) | Approved | Small molecule | HIV reverse transcriptase | ||
| Elvitegravir (Stribild / Genvoya (component)) | Approved | Small molecule | HIV integrase | ||
| Emtricitabine / Tenofovir Disoproxil Fumarate (Truvada) | Approved | Small molecule | HIV reverse transcriptase |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
January 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.